YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Thanks to our first-in-class science, leading IP position, agile discovery platform and seasoned team, we select the most promising gut bacteria and develop them toward Human clinical Proof of Concept. We have a diversified pipeline of biotherapies targeting obesity, IBD, mood disorders and oncology. Our lead program, Yso1, addresses obesity and we are completing a Phase 1 clinical trial in the US. We are pioneers in making drugs from the microbiome. You are looking for an exciting investment or partnering opportunity? Join us in our journey!
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):